Compliance questions, answered.

The Department of Health and Social Care closed its consultation in October 2023 and published its response in August 2025. A further public consultation was signalled for early 2026, with final regulations expected in Spring 2026. Phased rollout is anticipated from mid-2026 through 2027. Full enforcement — at which point unlicensed practice becomes a criminal offence — is expected from 2027. No statutory commencement date has been published. Operators should treat Spring 2026 as the point at which the rules become knowable, not the point at which they take effect. The window to prepare closes well before enforcement begins.

Both. The proposed scheme is not a restriction of practice to healthcare professionals. It is a competence standard that applies to every practitioner offering the procedures within scope, regardless of medical qualification. Non-medics will remain eligible to perform many treatments, subject to meeting the licensing standard and — for medium-risk procedures — operating under named clinical oversight. Medics performing in-scope procedures will also require the licence. The distinction the regulator is drawing is competence and accountability, not professional background. Anyone administering toxin or filler in England should expect to need a personal licence.

The proposed framework classifies non-surgical procedures into three categories by risk of complication. Green covers the lowest-risk treatments — minor chemical peels, microneedling — performable by any licensed practitioner meeting agreed standards. Amber covers medium-risk procedures including botulinum toxin and dermal fillers; non-medics may perform these only under the oversight of a named regulated healthcare professional. Red covers the highest-risk procedures, including BBLs and certain intimate-area treatments; these will be restricted to qualified healthcare professionals and may fall under CQC regulation rather than local authority licensing. The exact list of procedures in each category is still subject to consultation.

Yes. The scheme has been consistently described as a two-licence model. A personal licence authorises the named practitioner to perform specified procedures. A premises licence authorises the location at which those procedures are delivered. The premises licence will be assessed against hygiene, infection control, and clinical environment standards by local authority Environmental Health officers. Mobile practitioners, home-clinic operators, and clinics renting space within other businesses should expect particular scrutiny on premises licensing. Operating without either licence, once enforcement begins, will be a criminal offence.

Transitional arrangements are likely but not guaranteed. Government consultation responses have signalled that practitioners with recognised qualifications, professional body membership, and documented compliance will be in the strongest position when licensing begins. Industry expectation is that existing practitioners meeting baseline standards — Ofqual-regulated qualification, indemnity insurance, JCCP or equivalent registration — will be granted a transition window, often quoted as 12 to 18 months. This has not been confirmed in regulation. Practitioners who wait to see what grandfathering applies will be making a strategic bet against the regulator's tendency to use transitional periods as a filter, not a free pass.

Not currently. The government has stated there are no immediate plans to reclassify dermal fillers as prescription-only medicines. However, the Medicines and Healthcare products Regulatory Agency has indicated it intends to apply stricter rules to dermal fillers under UK medical device regulations, including controls on distribution and product standards. Operators should treat the regulatory direction as one of increasing — not stable — oversight. Sourcing, supply chain documentation, and product traceability are likely to be subject to greater scrutiny under the new licensing regime, even if prescription status itself does not change.

The minimum standard has not yet been confirmed in regulation, but the strongly signalled direction is an Ofqual-regulated qualification at Level 7 for injectables. The Health Education England framework for non-surgical practice is widely treated as the baseline reference. Level 7 Diplomas in Cosmetic Injectables, delivered by recognised training providers and accredited through Ofqual or a UK university, are the qualifications most likely to meet the standard at first issue. Two-day courses, in-house certifications, and qualifications not regulated by Ofqual or accredited through a recognised awarding body are unlikely to satisfy licensing requirements.

Specific penalties have not yet been published. The Health and Care Act 2022 enabling clause sets the framework for unlicensed practice to be designated a criminal offence, which would carry the possibility of fines, prosecution, and — for the most serious cases — custodial sentences. Insurers are expected to void indemnity cover for unlicensed practice, exposing the practitioner to personal liability on any claim. Local authority Environmental Health officers will conduct inspections and have enforcement powers. Operators should also expect commercial consequences: removal from approved-provider lists, loss of insurer-backed referrals, and reputational damage in a market where licensing status will be publicly verifiable.